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ABSTRACT
The discovery of the CRISPR/Cas system has provided scientist with an 
efficient, easy and site-specific method for gene editing. The main constraint in 
genetic modification was to create a double-stranded break in the DNA and to 
replace the mutated gene with the minimum possible off-target effects.   
Here, we systematically review the origin, function and uses of CRISPR-Cas9 
technology for gene editing. The literature reviewed shows its uses are endless,
from agricultural modifications to biotechnological applications. 
We also demonstrate CRISPR-Cas9’s potential with a case study in silico that 
replaces a mutated exon in the BRCA1 gene. This mutated exon is considered 
a pathogenic variant for hereditary breast and ovarian cancer and the idea is to 
correct it and prevent its transmission to the patient’s children. After identifying 
the genetic alteration that needs to be repaired, with the help of the 
corresponding online tools, we have designed highly specic guideRNAs (gRNA)
and a corresponding donor. The selected gRNA, complementary to the target 
DNA sequence, guides the Cas9 protein to the desired location with a high on-
target efficacy and reduced off-target effects. 
This technology has raised many ethical concerns that should be taken into 
consideration and are being examined worldwide such as the possibilities for 
germline editing and its ecological impact.
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INTRODUCTION:
Genetic engineering or genetic modification is the manipulation of the DNA in 
any organism. This could be achieved in different manners including altering 
one base pair (A-T or C-G), inserting a copy of a gene, deleting a region of DNA
or extracting DNA from one microorganism to combine it with another 
organism’s DNA.
For decades, genetic modification studies were limited to the analysis of 
spontaneous mutations. Then, Muller (1927) and Auerbach (1947) proved that 
with the use of radiation or chemicals the rate of mutagenesis increased (1,2). 
Later methods relied on the use of viral vectors to transfer genetic materials into
the cells. Once introduced into the nucleus of the host cell, the new genetic 
material was incorporated randomly into the genome. Therefore, these methods
of genetic modification were unreliable as the insertion site could not be 
controlled (3).
The first genetic modifications with a specific target were achieved in yeast and 
mice (4,5) as a result of the process of homologous recombination. This is the 
exchange of nucleotide sequences between molecules of DNA with similar base
sequences. This technique was precise but not efficient and was mainly based 
on the use of stem cells. 
The main constraint in genetic modification was the ability to create a double-
stranded break in the DNA, at the desired location and to replace the mutated 
gene with a minimum number of off-targets. 
During the 1990’s, it was found that specific nucleases could create a double-
stranded break in the DNA on a specific site in the genome (6). The first 
enzymes used were the zinc finger nucleases (ZFN), which have a cleavage 
and a DNA binding domain, and were proved useful for site-specific 
modifications of the genome in fruit flies and mice (6,7). By 2005, this 
technology was used to correct a mutation in a human cell (8). However, 
programming ZFNs to target a specific site was a slow process and not fully 
reliable. Several ZFNs did not efficiently recognize the target DNA sequences 
while others cut DNA sequences that were similar to its target, resulting in non 
desired mutations or even cell death.
By 2009, scientists started using transcription activator-like effector nucleases 
(TALENs) from the proteobacteria Xanthomonas for genetic modification (9,10).
They were remarkably effective compared to the ZFNs but as ZFN they 
required a different protein for each target DNA site and it was still a lengthy 
process.
All these studies showed a great potential in gene therapy research and for 
future treatments to many important human diseases. However, the processes 
were still time-consuming and costly. Thus, it was not until 2012 that the 
CRISPR-Cas system applications were discovered and an effective site-specific
method of gene therapy was possible.  
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What is CRISPR Cas?
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) are DNA
sequences joined with Cas (CRISPR-associated) proteins. This acronym 
pertains to the unique palindromic DNA sequences that are part of bacteria’s 
and other microorganism’s genome. These sequences are generally depicted 
as diamonds and squares. The diamonds represent the short repeats whilst the 
squares represent the spacers that interrupt the repeats regularly. Although 
CRISPR seemed innocuous, it was later discovered to be an essential piece of 
a bacteria's immune system against viruses.  
Fig. 1: CRISPR inside a bacterial cell. From (127)
The CRISPR-Cas system has the ability to recognize previous viral infections 
that the cell has come into contact with and uses the Cas protein to split the 
virus’s DNA and destroy it (see Fig. 2). The virus’s genome is essential for its 
replication, therefore, by splitting the virus’s DNA, the CRISPR system ensures 
bacteria will not endure an ongoing viral infection. 
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Fig. 2: Simple steps that show CRISPR’s immunity. From (134).
This system would then be studied in depth so it could be used as an effective 
tool for genome editing. 
OBJECTIVES:
1- To understand the origin, function and possible uses of the CRISPR/Cas 
technology for genome editing.
2- To demonstrate the potential of the CRISPR/Cas technology with a case 
study in silico by replacing an exon with a single nucleotide polymorphism 
(SNP) in the BRCA1 gene responsible for the tumorogenic effect.
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METHODOLOGY:
A systematic review, with inclusion and rejection criteria, was used to analyze 
the CRISPR’s origin and function. 
Inclusion criteria:
• Scientific articles with full text.
• Articles published in scientific magazines.
• Randomized clinical trials.
• Bibliographic reviews.
• Documents had to be available in English.
• Keywords:
          - CRISPR-Cas9 AND genetic modification.
          - CRISPR-Cas9 AND genetic engineering.
          - CRISPR-Cas9 AND treatments in embryos.
Rejection criteria:
• Articles that could not be obtained in full text.
• Documents that do not pursue the objectives intended.
The search was executed between the months of January 2018 and March 
2018. It focused on papers published by some of the most prominent experts on
the subject like Jennifer A. Doudna and Francisco J.M. Mojica.  
The web search was accomplished by combining the different keywords in the 
PubMed database. PubMed is a free database with publications of biomedical 
and life sciences literature at the U.S. National Institutes of Health's National 
Library of Medicine. It includes more than 28 million citations from MEDLINE for
biomedical literature, life science journals and online books. Citations may have 
links to its full-text content from PubMed Central.
A preselection of articles was executed through a reading of their abstracts, 
excluding those studies that didn’t follow the inclusion criteria previously 
mentioned. Then, an exhaustive reading of the full text of the remaining 
publications was completed so they could be thoroughly analyzed and included 
in the systematic review.
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The case study of BRCA1 gene:
Materials:
1. Crispr design available at http://crispr.mit.edu.
2. Human genome database available at http://genome.ucsc.edu.
3. The genomic sequence of the locus to be targeted.
4. SNP database available at https://www.snpedia.cmm.
5. Integrated DNA technologies webpage: https://eu.idtdna.cmm/paees/hmme.
6. Computer with an Internet connection.
Identifying your SNP in BRCA1:
It is imperative to identify the SNP that is causing an alteration on the BRCA1 
gene.  In this case study, the SNP database that was used was SNPedia: 
https://www.snpedia.cmm.
Using this database you learn the SNP’s position, the effect this variation of 
DNA has on humans and a description of the genetic alteration that needs to be
repaired.
Identification of target sites using CRISPR design:
As soon as you know the position of the SNP that is causing your genetic 
alteration you need to find it in a human genome database. The database used 
for this case study was: http://eenmme.ucsc.edu.
• Go to “genomes”
• Click on “Human CRCh37/hg19”. So the page takes you to the “UCSC 
Genome Browser on Human Feb. 2009 (GRCh37/hg19) Assembly”
• Here you can enter the position of your SNP.  
• You then press “zoom out” until you can see the region that needs to be 
replaced. If the SNP is within an exon, it is wiser to replace the whole 
exon to repair this genetic alteration.
• Select 240-250 base pairs in each intron on either side of the exon to be 
replaced. Click “view” and then “DNA” so you can obtain the DNA 
sequences at each side of the exon that will be used for the homologous 
recombination event.
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This will identify the CRISPR/Cas9 target sites as well as the donor DNA to 
replace the mutated exon.
The “CRISPR design” is a web page where you can enter any DNA sequences 
and it assists you in the process of CRISPR guide selection. It shows any 
possible off-targets in the whole genome, highlights guides with high target 
specificity and orders all possible guides scored by the inverse likelihood of off-
target binding.
To use the CRISPR design:
The database used for this study was: http:// crispr.mit.edu
• Go to the web page and enter your DNA sequence
• Choose a target genome. In this case study: human (hg 19)
• Click submit.
The DNA sequence will be processed to find possible CRISPR guides, 20 
nucleotides adjacent to a PAM sequence: NGG. It will also find any possible off-
target matches through the genome. Once this is all scanned you click “Job 
output” and you will obtain a list with all your possible guides scored by the 
inverse likelihood of off-target binding as well as a list of off- targets from each 
possible guide.
Fig. 3: Job output page from “CRISPR design”.
When a guide is chosen, the top 20 genome-wide off-target sites, are displayed.
Off-targets are organized by their affinity to the selected guide, taking into 
account the number of mismatches and the position of each mismatch, which 
are then highlighted in the DNA sequences.
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Guides with a score of 50 or higher are highlighted in green, this means they 
are considered good options as a targeted sequence. You then have to check 
that there aren’t any gene regions with a high off-target score. Guides 
highlighted in yellow could be used as backups if there are no suitable green 
guides, but they are not ideal. If, like in this case, you are trying to make a cut 
on the introns around an exon, you could look further up or down the DNA 
sequence, to see if there are any guides highlighted in green. Guides 
highlighted in red should be avoided because they have many off-target 
interactions.
Designing of the Donor:
Once you have your guides, you need a donor sequence. The donor sequence 
will be the one to replace the DNA sequence with the mutation. For this to 
happen, the donor needs to have the whole exon, without the mutation, and 
homology arms of 200 base pairs.
• Go to the web page: http://eenmme.ucsc.edu.
• Select all the DNA between one guide and the other.
• Click “view” and then “DNA”.
• Add 200 base pairs on each side
• Copy this DNA sequence.
• Change your PAM sequences, so the Cas9 nucleases will not cut your 
donor sequence once it integrates.
To obtain your donor you need to submit your DNA sequence to a company for 
synthesis. IDT (Integrated DNA technologies) is amongst the most specialized 
companies in this regard and the one preferred by many laboratories. They will 
then deliver your sequence as a single-stranded DNA.
• Go to the web page: https://eu.idtdna.cmm.
• Click on “products and services” and “single-stranded DNA fragments” to
obtain your donor.
• Click on “CRISPR genome editing” and “Alt-R CRISPR-Cas9 System” to 
obtain your RNA-guides.
“Alt-R CRISPR-Cas9” provides essential tools for genome editing studies. You 
can also obtain Cas9, tracrRNA and RNA guides by providing them with your 
guide sequences.
Once you’ve bought all the required materials from “Alt-R CRISPR-Cas9” you 
could carry out your experiment in vitro. Zygotes with this precise mutation 
could be edited by inserting this genome editing tools through electroporation.  
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Systematic review:
Origin
The history of CRISPR-Cas began in 1987 in Japan, when Atsuo Nakata's 
group found a previously unidentified structure in Escherichia coli (Gram-
negative bacteria) that consisted of palindromic structures separated by 
similarly sized spacers (11,12).
A similar structure was discovered in the Mycobacterium tuberculosis complex 
(Gram-positive bacteria) (14). These are bacteria with a big genetic distance 
from E.Coli. However, the importance of this connection was not realized until 
1989, when Francisco Mojica, from the University of Alicante (Spain), found in 
archaea: Haloferax Mediterranei similar structures to those reported by 
Nakata’s group.  Mojica found a structure with short palindromic repeats of 30 
bp separated by spacers of around 36 bp (13) and realized that, if such similar 
complexes were present in microbes with such a vast evolutionary distance, 
they must be of great importance. 
From 1996 to 1999, Mojica discovered many more of these structures in other 
archaea and bacteria. By 2000, he had found them in 20 different 
microorganisms and named them Short Regularly Spaced Repeats (SRSR)
(14). The study of SRSR’s loci in many archaea and bacteria led to the 
discovery of four genes close to the SRSR, cas1- cas4, that were presumed to 
have a related function (15).
In 2002, Mojica changed the acronym to CRISPR (Clustered Regularly 
Interspaced Short Palindromic Repeats) after the bioinformatic analyses 
established that the palindromic repeats occurred in clusters, with spacers of 
the same extent lengthwise (15, 16). 
CRISPR is a part of the microorganism's immune system
Mojica then focused on the spacers between the repeats. After introducing them
into the BLAST program, he found a match between one spacer and a 
bacteriophage that infected E. coli.  Therefore, he was the first to suggest that 
CRISPR were homologous to the viruses that infected those bacteria. He 
revealed, that those bacteria with fragments of viruses inserted in their 
genomes, were resistant to the infection of those particular viruses (17). Other 
laboratories confirmed this theory(18,19) and they all concluded that CRISPR 
must be part of bacteria’s immune systems (17).
The sequences extracted from viruses and stored by the bacteria between the 
spacers were referred to as protospacers. Studying the spacer sequences they 
realized there was a small part of DNA retained next to the protospacers, which 
would later be referred to as PAM (protospacer adjacent motif) (20). They 
hadn’t yet realized why PAM was important but it was certainly essential for the 
CRISPR system, since it appeared next to all the protospacers.
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Parallel to this study, Phillippe Horvath, a Ph.D. student at the University of 
Strasbourg, started working for Rhodia Foods. Horvath wanted to eliminate the 
frequent bacteria infections that affected the dairy fermentation process. 
Therefore, he focused his studies in cresting a method to detect precise strains 
of bacterial DNA resistant to viral attack. Once he learned about CRISPR, he 
started working with Rodolphe Barrangou and Sylvain Moineau to test the 
hypothesis that the CRISPR was part of the bacteria´s immune system (21).
In 2007, they were able to confirm their hypothesis with a study using the 
bacteria Streptococcus thermophilus and two bacteriophages. They conducted 
a series of experiments where they added the spliced phage’s DNA into the 
bacteria’s CRISPR region. They then checked if these bacteria were resistant to
that particular bacteriophage (21). Understanding how bacteria could recognize 
and destroy those phages during future infections was the key to acquiring 
immunity against the bacteriophages in the dairy industry.
This posed further enquiries such as: How was the genetic material being 
destroyed? How was it being recognized and targeted? All these questions led 
to the search of other components of the CRISPR system.
Focusing their studies on the proteins encoded by the cas genes, they 
discovered the Cas7 and Cas9 proteins and their functions. On one hand, Cas7
was required for the acquisition of new spacers but it was not involved in the 
cutting of the invading DNA. On the other hand, Cas9, previously referred to as 
csn1, produced a large protein with two nuclease motifs (HNH and RuvC). It 
was presumed to be the protein responsible for cutting the invading DNA (19, 
22) and therefore essential for the bacteria’s immunity.
While some scholars focused their studies on Cas proteins others looked into 
how the genetic material was being recognized and targeted. This led to many 
investigations about the RNAs possible implication in this system.
RNA’s are a part of the CRISPR system
Stan Brouns, postdoctoral at the University of Wageningen in the Netherlands, 
and John van der Oost focused their studies on RNAs involvement in the 
CRISPR system. By 2008, they proved that CRISPR arrays were converted into
long RNA strands, which matched the sequence of CRISPR’s DNA. These long 
strands were then cut by an enzyme into shorter RNA strands of the same 
length. This smaller pieces of RNA (13,23, 24) differed from each other by the 
sequence contained in their spacers. Each spacer contained a sequence 
acquired from a different phage. Therefore, CRISPR RNAs (crRNAs) were 
essential for the bacteria’s immunity (25). To prove the hypothesis that crRNA’s 
made a complex with Cas proteins and were then guided to the viruses DNA, 
they started a study with E. Coli (25). In their study they programmed CRISPR 
(the first artificial CRISPR) to target four genes in the E. coli bacteriophage. 
Their results suggested that the E. Coli DNA was the target of this crRNA Cas 
complex, since it was then proved to be resistant to the virus.
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Luciano Maraffini and Erik Sontheimer, also confirmed that DNA was the target 
of this CRISPR system. They were the first to realize this system could be 
remodeled and used for genome editing in eukaryotic cells (26).
Other discoveries about this system’s function were made by many other 
experts in the field. Sylvain Moineau in collaboration with Danisco discovered 
Cas9 made a double-stranded cut in DNA. They also realized the PAM 
sequences were an important part of the process (27), since they appeared to 
be a recurring occurrence in many complexes (20,28). They noticed the DNA 
was always cut in the same location in relation to the PAM sequence.
Emmanuelle Charpentier and Jörg Vogel discovered that there was another 
small RNA implicated in the process. This RNA molecule was named trans-
activating crRNA (tracrRNA) and it merged with crRNA. Once both RNAs 
merged the RNaseIII processed them into their mature products. Several 
experiments confirmed tracrRNA was crucial for the crRNA to function therefore
essential for the CRISPR system (29).  Later investigations showed tracrRNA 
had another function. It was essential for a bridge to be created between crRNA
and the Cas proteins, so the Cas proteins could then cleave DNA (30,31).
Classifying CRISPR
The acquisition of progressively more information on the CRISPR Cas systems 
led to their classification. They were classified depending on their function and 
composition into type I, type II and type III (32,33).  
Studies showed many Cas proteins in type I and type III systems (25, 34- 38), 
while  type II systems only used one Cas protein (30, 39). This attribute that 
would later on prove really useful. Furthermore, the protospacer adjacent motif 
(PAM) was only a part of type I and type II systems (17, 20, 27, 40).   
Since more proteins were discovered and their behavior was further analyzed,  
they created a new classification, where Class 1 was constituted of types I, III 
and IV while Class 2 included types II and V (41). Class 2 only needs one 
protein, Cas9, for it to recognize its target and make the necessary DNA cuts, 
while Class 1 need a multitude of protein complexes (42). TracrRNAs are also 
exclusive of Class 2 systems. Both these qualities explain why they selected 
type II CRISPR Cas systems to be studied in depth and tried to use its 
components to develop the technology necessary for targeted DNA cleavage.
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Fig. 4: Functional classification of Cas proteins. From (41). 
Transferring CRISPR between organisms
Vigjinijus Siksnys and collaborators, trying to examine if we had all the elements
necessary for the CRISPR Cas system, conducted an experiment were the 
CRISPR Cas system from S. thermophilus was transferred to a microbe with a 
great genetic distance, E. coli.  Until this study in 2011, the CRISPR Cas 
system had only been investigated in the bacteria that contained them. Their 
results were outstanding, the immunity got transferred from S. thermophilus to 
E. Coli (43). This confirmed that CRISPR Cas systems could be transferred 
between species, since these two microbes have a greater genetic distance 
than the one between humans and yeast (44, 45) and they could be adapted to 
target specific sequences (43).
This was a major breakthrough in the CRISPR study. Once all the constituents 
of the CRISPR system were recognized (crRNA, tracrRNA, and Cas9 proteins), 
scholars were ready to perform accurate biochemical investigations.
Crispr in vitro
By 2012 two teams of scientists assessed the behavior of CRISPR/Cas 
systems in vitro and both came up with the hypothesis that their components 
could be used to edit genomes (30,39).
Jennifer Doudna at the University of California Berkeley and Emmanuelle 
Charpentier in Sweden started working together and studied the function of S. 
pyogenes CRISPR-Cas9 system’s components (Cas9, tracrRNA, and crRNA). 
They focused their study on how these molecules acted together to destroy viral
DNA.
Isolating the Cas9 protein they demonstrated that it was able to cleave DNA in 
vitro. Cas9 proteins contained two domains (HNH and RuvC) which cut the 
opposite strands of the DNA, achieving a double-stranded break (DSB). 
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This cleavage took place in the specific DNA sequence homologous to the 
crRNA spacer region.
Furthermore, they employed effective custom-built crRNAs and verified both 
crRNA and tracrRNA were necessary for cas9 to accomplish its purpose. In 
addition, they established how tracrRNA and crRNA could be fused into a single
guide RNA (sgRNA) retaining both of their properties. This extraordinary 
discovery made it possible for us to have an uncomplicated programmable 
RNA-guided genome editing tool (30).
Fig. 5: Cas 9 creates a double-stranded break guided by a single guide RNA. 
From (135).
Around the same time, Siksnys, Barrangou, and Horvath worked together and 
studied the activity of S. thermophilus’ type II systems in vitro (39). Like Doudna
and Charpentier they proved that the DNA could be cut in vitro with a double-
stranded cleave, three nucleotides away from the PAM sequence. In their 
research, they created custom-built spacers that would lead the Cas9 protein to 
cut whatever gene they chose. Their evidence also proved that the Cas9’s NHN
domain was responsible for the cutting in the DNA strand that was 
complementary to the crRNA, while the RuvC domain was responsible for the 
cut in the opposite strand. Moreover, they showed that the crRNA could be 
shortened up to 20 nucleotides and still be effective (31).  They recognized the 
potential of this technology and suggested that it could be used to perform DNA 
surgery using programmable RNA guides (39).
Both teams published their findings by 2012, inspiring many scientists to prove 
that RNA- programmable DNA endonucleases could be used as a tool to edit 
the genome in mammalian cells (46).
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Genome editing
Three main groups of investigators, one led by Luciano Marraffini (47), another 
by Feng Zhang (48), and the third one by George Church (49) focused their 
studies on the use of CRISPR technology to edit the mammalian genome.
Feng Zhang was working with TALENs when he learnt about CRISPR. He 
started using CRISPR Cas9 tools derived from S. thermophilus to use in human
cells. By 2011, he used this technique to target the luciferase gene in human 
embryonic kidney cells, but the decrease in luminescence was small. So, he 
tried to improve the technique by considering ways of increasing the amount of 
Cas9 that accessed the nucleus. He became aware that the cas9 from S. 
thermophilus had an irregular dissemination within the nucleus and by testing 
alternatives he realized that the Cas9 from S pyogenes was more evenly 
distributed. He also discovered that even though human cells don’t possess 
RNaseIII they could still use crRNA. By 2012, he had effective components for 
this technic: a CRISPR array, Cas9 from S. pyogenes and tracrRNA. In his 
investigations he targeted 16 loci in human and mice cells and found he could 
mutate genes, deleting genes by non-homologous end joining and inserting new
genes by assisted recombination. He also realized several genes could be 
edited at the same time and when he read Charpentier and Doudna’s 
investigation he tried the sgRNA that they used in their in vitro study. The 
sgRNA didn’t work as expected in vivo, it didn’t cut many of the loci, but he 
realized that a full-length fusion was effective (48, 50). Zhang showed how 
versatile this technology could be: it could be used to create personalized mice 
models of someone’s specific genetic disease or cancer in weeks. It could also 
help us locate all the required genes for any biological system. Furthermore, he 
found more class 2 CRISPR systems, even one with a different nuclease than 
Cas9, that didn’t need tracrRNA to function (51).
At the same time, George Church, a Harvard professor, who had collaborated 
with Zhang also did an investigation on how to edit the human genome. Like 
Zhang, he tested fusions of crRNA- tracrRNA and realized short fusions did not 
work out in vivo, while full-length fusions were effective. In his study, he 
targeted seven loci, mutating genes by non-homologous end joining and 
homologous recombination (49).
Using Church’s sgRNA, Keith Joung, a Harvard professor, experimented with 
CRISPR technology on zebrafish. He determined it could be used to effectively 
produce mutations in the germline (52).
This were the initial studies, but later on, CRISPR Cas technology was used on 
several types of cells and organisms (Table 1).
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Table 1: First cell types and organisms that had their genomes edited with 
CRISPR-Cas technology. 
This table continues to grow. Scientists have used CRISPR to modify the 
genome in hundreds of plants and animals.
It’s hard to compare the effectiveness of the studies since they have got 
different target sites but there are analysis reporting that the efficiency can 
reach up to 80% or more, more than what we obtained using ZFNs or TALENs 
(52,53).
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Table 2. Timeline of the key discoveries that led to the CRISPR-Cas9 
technology (1987–2013)
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Year Discovery Reference
1987 First discovery of CRISPR in Gram negative bacteria. 11
1991 First discovery of CRISPR in Gram positive bacteria. 14
1993 First discovery of CRISPR in archaea. 13
2000 CRISPR are named short regularly spaced repeats (SRSR) 14
2000 Many short regularly spaced repeats are discovered in several 
 bacteria and archaea, which suggests an important pupose. 14
2002
(Clustered Regularly Interspaced Short Palindromic Repeats) 16
2002 Discovery of Cas genes. 15
2005 First finding that CRISPR spacers matched sequences in
bacteriophages and plasmids. 17
2005 First hypothesis that CRISPR-Cas systems were a part of the
bacteria’s immunity.  21
2007
adaptive immunity against bacteriophages. 21
2008 Experiments prove CRISPR Cas systems target DNA. 22
2008 First discovery that small RNA’s form part of the CRISPR 
system as guides. 25
2008 They realize the protospacer adjacent motif (PAM) has a
crucial role in the CRISPR-Cas system. 27
2010
locations due to Cas proteins in the CRISPR-Cas system. 30
2011 Discovery of a new small RNA that was part of the CRISPR
system, the trans-activating CRISPR RNAs (tracrRNAs). 29
2011 Transferring CRISPR Cas sytems to a genetic distant organism:
43
2012 First experiments to asses CRISPR Cas systems in vitro and
scientist suggest it’s components could be programmed and be
used to edit the genome in mammalian cells. 30,39
2013 First successful experiments were CRISPR Cas’s
constituents were used to edit the genome of mammalian cells. 47,48,49
 Regularly spaced repeats acquire a different name CRISPR
 Experiments prove that CRISPR-Cas systems are part of an
 First explanation about how DNA is cleaved at precise
from S. thermophilus to E. coli.
Mechanism of the CRISPR-Cas system:
The CRISPR systems in bacteria
Currently, the Type II CRISPR systems are the basis for the genome editing 
technology.  
Fig. 6: The key steps of CRISPR-Cas’s immunity. From (136)
The CRISPR Cas immunity process can be split into three phases: adaptation, 
expression, and interference (Fig. 6). The CRISPR contains short repeated 
sequences that are separated by spacers. These spacers are acquired from 
viruses DNA and this is what happens in the first step of the CRISPR Cas 
immunity process, adaptation. By attaching more spacers new viruses can be 
identified, therefore, more viruses genomes can be recognized and destroyed 
by the bacteria. Spacer acquisition modifies the genome, therefore the offspring
will inherit the immunity.  
Adjoining the CRISPR array there is a group of CRISPR associated genes that 
code for proteins indispensable in this immune system. Moreover, CRISPR is a 
chronological record of the viruses the bacteria have come into contact, due to 
the new spacers getting added at one side of the CRISPR. The key 
components of spacer integration are Cas1 and Cas2 genes and their 
subsequent proteins (21,25). This genetic memory is crucial for the following 
phases, expression, and interference, to destroy the re-invading genetic 
material from viruses.
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During the second phase, expression, Cas genes are expressed and their 
proteins formed. The CRISPR is also transcribed and a long precursor CRISPR 
RNA (pre-crRNA) is formed. The pre-crRNA is then processed by Cas proteins 
into small mature crRNAs. This crRNAs contain a single spacer each and the 
Cas protein responsible varies with each type of system (54).
Type 2 systems have a different mechanism than the other systems, for the 
biogenesis of crRNA. They transcribe a second RNA, tracrRNA, that pairs with 
the pre-crRNA and both get processed together by the RnaseIII (29) In addition,
they have got another distinct feature, they require the Cas9 protein for its 
immunity (29, 30).
The comparison of the three types of CRISPR systems shows that Types I and 
III had different mechanisms to obtain their immunity, they used Cas6 proteins 
instead of Cas9 and processed pre-crRNA differently (34).
In the third stage, interference, the nucleic acid from the virus is recognized and
eliminated with the aid of the crRNA and the Cas proteins. Target interference is
based on the ability of the crRNA, bound to the Cas protein, to locate the 
corresponding spacer to set off the disintegration of the target. The 
disintegration is executed by specific Cas nucleases (25,55).
Types I and II systems need a PAM sequence present adjacent to the spacer 
and require a perfect complementarity between the spacer and the crRNA 
(56,57,58). The crRNA joins one of the strands of DNA by base pairing and the 
non bound DNA strand is displaced and forms an R-loop (59). The Cas protein 
then cuts the target DNA and degrades it. In Type I systems it is the Cas3 
nuclease the one needed for interference (22, 25, 33), while type II systems 
only require Cas9 proteins. The Cas9 protein contains 2 nucleases domains the
HNH and RuvC which will cleave the complementary and non-complementary 
strands of DNA, respectively (60).
Type II systems will also require the tracrRNA joined with the crRNA and Cas9 
protein to perform the recognition and degradation of the target (29). 
Type III systems undergo a different process to the PAM recognition in types I 
and II. Since these systems do not have PAM sequences, they recognize the 
target by extending the crRNA base pairing with the host DNA (61).
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Fig. 7: Class 2, Type II CRISPR- Cas9 System from Streptococcus 
thermophilus. From (137). 
(A) The locus consists of the CRISPR array with black diamonds representing 
the repeat regions and colored squares for the spacers, four genes (cas9, cas1,
cas2 and csn2) that will code for four different proteins and the tracrRNA. (B) 
The CRISPR array and tracrRNA are transcribed so a pre-crRNA and a 
tracrRNA are formed. (C)  Both RNAs merge and are cut into shorter pieces by 
Cas9 and RNase III. (D) There is a complex formed by Cas9, tracrRNA, and 
crRNA that will search for the matching DNA sequence from the spacer 
(showed in red). For this complex to bind to their target it requires a three 
nucleotide sequence named PAM, were the Cas9 will attach itself.  (E) Once 
Cas9 it attached it will create a double-strand break as a result of its two 
endonuclease domains (HNH and RuvC) cutting opposite strands.
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Applications of CRISPR technology for genomic editing    
With this remarkable technology scientists found a simple way to rewrite any 
genome, and showed that the possibilities were endless. As long as the guide 
RNA matched the 20 bps in the DNA and the cas9 was present any cells’ 
genome could be edited. Scientists used this new technology in many different 
ways:
- To functionally assess the mutations in mice genomes. Since mice are 
genetically speaking very related to humans and are small, they are the perfect 
test subjects for animal research. This is crucial to gain a better understanding 
of human diseases and test the efficacy of potential drugs or medical 
interventions (62, 63, 64, 65). 
- To create genome edited primates (66).
- To improve the quality and quantity of crops, fruits, and vegetables. CRISPR 
has already been used to make wheat resistant to a certain type of bacteria 
(68), to confer potatoes the ability to not sweeten during storage (69), to 
generate soy plants that produce oils with less LDL (70) and to produce 
mushrooms that do not spoil prematurely (71). 
- To edit the genome in livestock for biomedical [90] and agricultural purposes 
[91]. Scientists have created cows with 20% more muscle, with less fat and 
more amount of meat (72). This small change in livestock’s genomes can result 
in an increase in the production of food. Their genome can also be edited to 
make them healthier or have a better resistance to diseases. Other examples of
gene-edited livestock are genetically dehorned cows (73), pigs with an 
increased resistance to viruses (74) and goats with longer hair (75).
- It is possible to inactivate multiple genes that could provoke a reaction from 
the human’s immune system in porcine cells, for xenotransplantation purposes. 
There is a shortage of organs and many people die while they are waiting to 
receive a transplant. Even if this has not yet been done in any human clinical 
trials the results with baboon recipients have been promising (76).
-  Thanks to CRISPRs ability to insert o delete part of a gene it can produce an 
alteration in the genes ability to create a functional protein. This is referred to as
a gene knockout or KO. Therefore it is possible to manufacture a lentiviral 
knockout CRISPR library of thousands of single guided RNA sequences which 
are able to knock out specific genes. This facilitates the identification of genes 
required for a specific biological response as well as of potential drug targets for
diseases (77,78,79).
- To build gene drives, so the DNA that is inserted into the cell contains the 
genetic information that encodes CRISPR. Scientists have already used the 
gene drives to give mosquitoes a resistance to Plasmodium falciparum and to 
spread genes for sterility in female mosquitoes, which could potentially 
eradicate the entire species. This technology could be used to eliminate many 
diseases which have mosquitoes as vectors, like malaria, dengue, Zika virus 
and many others (67). Recently, gene drives have also been reported in mice 
(131).
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Fig. 8:  Comparing natural inheritance to gene drive inheritance. From (138).
- To reproduce chromosomal rearrangements, large inversions, and 
translocations observed in patients that were extremely difficult to model in 
human cells (80) and in mice (81).  This has made it possible for us to replicate 
a patient’s cancer, such as lung cancer (82), acute myeloid leukemia (83) and 
Ewing’s sarcoma (84). Thus, it’s possible for us to study cancer’s and other 
disease’s development and progression.
- To edit nonviable human embryos so it is possible to study our genome (85).
- To create protocols for in vivo genome editing (86) and studying possible 
therapies for devastating genetic diseases in animal models and human cells. 
Some examples in which its use was successful are the modification of a 
mutation in the Crygc gene that was responsible for cataracts in mice (87) and 
to cure mice of other genetic affections such as muscular dystrophy (88, 89) 
and several metabolic disorders (90). In cultured human cells, CRISPR was 
able to repair many genetic diseases like sickle cell disease, hemophilia, cystic 
fibrosis, and severe combined immunodeficiency (91, 92, 93, 94) and very 
recently progeria (132).
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- To edit the CCR5 gene and therefore preventing the HIV from latching onto it 
and to remove viral genes from infected cells (95).
- To further understand cancer and determine which mutations cause 
tumorigenesis quicker (96). 
- To edit induced pluripotent cells (iPS) that can later be the ideal cells for 
autologous cell replacement on humans with a previous genetic disorder (97, 
98).
- To create gene therapies for human diseases (99).
Other applications of CRISPR technlogy
- There are other applications to this technology, not just gene editing. 
Scientists created a version of Cas9 without its endonuclease activity, therefore 
without its ability to make a cut in the genome. It can still locate specific DNA 
sequences and once they are located gene expression can be controlled. This 
was called CRISPR interference (CRISPRi) and it can repress the expression of
specific genes or even increase its output. It can prevent the RNA polymerase 
from binding, stop the transcriptional elongation or block a transcription factor.  
It has been used to repress the expression of multiple genes simultaneously, its
effect can be reversed and it is highly specific (100,101,102).
Fig. 9: CRISPR interference system’s use in controlling gene expression. From 
(139).
- This inactive version of Cas9 can also be fused to a fluorescent protein so you
can visualize genes involved in specific biological processes. (103)
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CASE STUDY RESULTS:
Genetic alteration to be repaired:
This genetic alteration is a variant considered pathogenic for hereditary breast 
and ovarian cancer syndrome.
The SNPs database “SNPedia” describes its position, the exact alteration in the 
DNA and the recommended actions if it is clinically confirmed.
SNP: rs886040335
It is a single nucleotide variant (A; G). The mutated codon, TGA,  produces a 
stop codon instead of the tryptophan that produces the non-mutated codon, 
TGG.
Nowadays the recommended action for someone with this mutation would be 
to:
• From 25 years onward, get intensive screening for breast and ovarian 
cancer.
• Bilateral mastectomy as a prophylactic surgery, to reduce the 
appearance and mortality from breast and ovarian cancer.
• First degree relatives should get tested for this mutation and should 
increase their screening.
BRCA1 variant cmnsidered pathmeenic fmr breast cancer
Is a eenmtype
mf rs886040335
Gene BRCA1
Chrmmmsmme 17
Pmsitimn 43.094.568
Maenitude 6
Repute Bad
Geno Mag Summary
(A; G) 6 BRCA1 variant cmnsidered pathmeenic fmr breast cancer
(G; G) 0 cmmmmn in clinvar
TABLE 3: Summary of the case study’s SNP in the BRCA1 gene. 
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Design of the gRNAs:
With the exact position of this SNP (43.094.568), you can go to the genome 
database to locate it. Once you zoom out you see this SNP is a part of the exon
9 in the BRCA1 gene. This is the exon we have to try to replace by cutting the 
DNA on the introns at both its sides. To cleave at both sides, two guide RNAs 
need to be designed.
By using CRISPR design you can obtain all possible guides scored by the 
inverse likelihood of off-target binding. The best guides would be “guide 1” at 
both sides, both ideal candidates since they have a quality score above 50 and 
are highlighted in green. This will be the gRNAs needed to guide the Cas9 
nuclease to the exact point in the genome where it needs to cut.
Fig. 10: All possible guides at the left side of exon 9 from the BRCA1 gene.
Guide one is showed in purple.
Guide 1:
• quality score: 92
• guide sequence: CTCTGTCAAATGTCGTGGTA(TGG)
• On target locus: chr17:- 41247704
• number of off-target sites 91 (9 in genes)
Fig. 11: All possible guides at the right side of exon 9 from the BRCA1 gene.
Guide one is showed in purple.
Guide 1:
• quality score: 72
• guide sequence: CTTGAACTCATGACCTCAAG(TGG)
• On target locus: chr17: 41248171
• number of off-target sites 163 (10 in genes)
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Design of the donor:
The DNA between both RNA guides needs to be replaced by a donor without 
the mutation. Using the genome database you can obtain the DNA sequence 
between both RNA guides and add 200 base pairs as homology arms.  
ssDONOR
>hg19_dna  range=chr17:41247504-41248381  5'pad=200  3'pad=200  strand=+
repeatMasking=none
TGGGAGGATAGCTTGAGCCTTGGAGGTGGAGGTTGCAGTGAGCCAAGATT
GCATCACTGCACTCCAGCCTGGGCAACAGAGTGAGACCCCATCTCAAAAA
AAAACAAACAAACAAACAAAAAAAAAAACGAAAGGGCAACAATCAGTTAC
AGAAGGTCTTATTATAGGTACATTAGTCTAGTACCATTTAAATCTATCAG
ACCATACCACGACATTTGACAGAGAATGATACTCTAACTCTGCCAAGAGA
TTTTGTGGGTTGTAAAGGTCCCAAATGGTCTTCAGAATAATCTAATTACA
GTACTGTATCTACCCACTCTCTTTTCAGTGCCTGTTAAGTTGGCAAACTT
TGCCATTACCCTTTTTTGCAGAATCCAAACTGATTTCATCCCTGGTTCCT
TGAGGGGTGATTTGTAACAATTCTTGATCTCCCACACTATAGGGAAAAGA
CAGAGTCCTAATAAGAAACACTAGTTACATGTATGCAGAACTGTCAAATG
ACCAAGATCAAACATTTTAGCTCTTTCGATTACAGAAAGCTGACCAATCT
TATTTAGTTAGTGAAAGCTGCTCTCTCCTTTAGAAACTTCTAGTTGAAAT
GAAATGGTTGCTGGGCACGGTGGCTCAAGCCTGTAATTCCAGCACTTTGG
GAGGCTGAGGCGGGTGGACCACTTGAGGTCATGAGTTCAAGACCAGCCTG
GCCAACATGGTGAAACCCCATCTCTACTAAAAATACAAAAATTAGCCGGG
TGTGGTGGCGCGCGCCTGTAGTCCCAGCTACTAGAGAGGCTGAGGCAGGA
GTATGGCTTCAACCTGGGAGGCAGACGTTGCGGAGAGGTGAGATCACACC
TCTGTACTCCAGCCTGGGCAACAGAGCA
• Purple for the homology arms.
• Red for the RNA guides with the PAM sequence highlighted.
• Black for the DNA between both RNA guides.
• Green for the exon with its mutation highlighted.
This single stranded donor DNA is generally obtained from a company, in our case
from IDT (Integrated DNA technologies). Before ordering it, both PAM sequences need
to be changed, so Cas9 will not eliminate the donor once it is incorporated. Thus,
the CCA changed to TGA. The rest of the donor sequence needs to stay exactly
the same.
IDT can provide you with all the necessary tools to carry out this case study in
vitro.  You can buy Cas9 nuclease and get your exact gRNA and donor if  you
provide them with the precise DNA sequences.
Reagents  are  injected  in  the  cytoplasm of  the  zygote,  preventing  the  genetic
alteration transmission to the patient’s children. Alternatively, these can be injected
in the pronucleus of the zygote, but cytoplasmic microinjection is simpler. 
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DISCUSSION: 
Possibilities of the technology and perspectives:
Research on genome editing will continue until it becomes an invaluable tool in 
many aspects of our life. But will CRISPR-Cas9 be the definite programmable 
nucleases or will we find something more efficient? 
CRISPR-Cas9 is a simple technology, with a single protein to cleave the DNA 
and recognition of the exact target by base pairing, so it is hard to envision a 
more efficient way to edit the genome. There is the possibility of finding a 
chemically-based reagent that combines the DNA split and the DNA 
recognition. This has been researched for decades, with many different 
proteins, without successful results (104,105,106). Therefore CRISPR-Cas9 
and variations from this technology seem to be the future in genome editing.
There are many useful applications for this technology in the agricultural sector, 
with both livestock and crop plants. These genetically modified organisms differ 
from GMOs in crucial ways (107). Current GMOs are created by using different 
chemicals on seeds and selecting the plants with the desired traits, without 
being certain of other changes that might have occurred in the DNA of that 
plant. Now, due to this new technology we can select the desired genetic 
material and insert it in a precise location, making it a more accurate technique. 
Moreover, in most cases, these changes are ones that could have occurred 
naturally and there is no need to insert genetic material from other species. 
 
The already edited crops like disease resistant wheat (68), mushrooms that do 
not spoil or soy plants that are more nutritious for human consumption (70) are 
just the starts to healthier and more proliferate crops. Cows edited to develop 
without horns (73) and sheep (72), pigs (108) and cows (72) with less fat and a 
higher percentage of muscle are the beginning of genome editing in livestock to 
improve animal and human welfare. The disruption of a single gene may result 
in an increase in food production. Will the public have a better acceptance of 
this technology than GMOs? Current aversion to GMOs is generally based on 
the greed and power of certain businesses, not on evidence of adverse effects. 
The public will have to decide what is more important, the process or the 
product? If CRISPR-Cas9 and its variations can protect livestock from deadly 
viruses, banish practices such as dehorning and increase food production we 
should consider the many benefits to both humans and animals before 
categorizing it as “another GMO”.
Beyond agricultural modifications, animals genome are being edited to produce 
models of human diseases to increase our knowledge of their biological 
processes and to test drugs and other therapies.(109) Companion species are 
likely to have their genome edited too, to create new breeds or to cure breeds of
their genetic predispositions to certain ailments.(110) 
29
Furthermore, a new line of work called “de-extinction” is being developed, with 
projects such as the Woolly Mammoth Revival in George Church’s laboratory. 
The idea that animals that have become extinct could be reintroduced into their 
natural habitat is an appealing concept to the scientific community. A genetic 
modification of an existing organism would have to take place, for example, to 
create the woolly mammoth several genetic changes are being introduced into 
the Asian elephant cells (111). Researchers will not only create the woolly 
mammoth, or some Asian elephant hybrid, they will do the same to many other 
species soon. The possibility of bringing back dinosaurs is still remote because 
nobody knows the DNA sequence that encodes them. 
Fig. 12: The de-extinction process starts in silico and ends in situ. From (140).
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Another future application for this technology relies on its use as gene drives. A 
genetic modification can spread through a population passing down the 
alteration to all its descendants. This is possible because the genetically 
modified animal contains the altered gene, the genes for the Cas9 enzyme and 
several guide RNAs that tell it where to cut. When the modified animal comes 
into contact with the wild species it modifies their DNA so all their descendants 
will contain the same alteration. This gene drives have already been developed 
in mosquitoes, producing sterility in their females (112) and inactivating genes 
required for parasites to grow (113). There are many countries with mosquito-
borne diseases that could benefit enormously with this approach because it 
could reduce the transmission of malaria, dengue, Zika virus, etc. This has 
raised many concerns, even if these diseases could be eradicated, the 
consequences of eliminating an entire species are unpredictable (114, 115). We
can not anticipate the consequences it would have on other species that rely on
those mosquitoes. Moreover, we can not foresee if the drives will become 
ineffective by adaptation or mutation in the organisms. Laboratory tests can not 
predict the impact of gene drives, the only way to see reliable results is by 
releasing them into a natural environment. Therefore, in the near future humans
will have in their hands the technology to easily eradicate whole species that 
are vectors to many human diseases.  We will have to decide if the benefits 
outweigh the risks.  
The possible medical applications for this technology are countless. CRISPR-
Cas9 could be used in germline editing, so genetic diseases will not manifest on
patients or their descendants, as well as in somatic therapies, to cure diseases 
in fully developed patients.
Somatic therapies greatest challenge is the delivery of the gene-editing 
technologies to certain cells in our organism, affected by a particular genetic 
disease. Ex vivo gene therapy is a simpler approach because cells can be 
removed from the patient, edited and then tested to see its efficacy before 
reintroducing them into the patient. Clinical trials to edit blood cells to cure beta-
thalassemia and sickle cell disease are starting this year in Europe since there 
have been promising results with monkeys (116). Genome editing has also 
been used as a therapy to eradicate HIV. The first clinical trial used ZFNs to 
knock out the CCR5 gene, the one responsible for producing the CCR5 protein 
where HIV latches onto (117). Due to the encouraging results of this trial, other 
clinical trials were approved to remove HIV with CRISPR-Cas9 (118, 119). 
Although the experiments are just starting they are encouraging and this 
technology could prove to be the ultimate solution to cure HIV.
While in vivo gene editing is currently not ready for clinical trials because we 
have to figure out how to deliver CRISPR-Cas9 to the affected cells and not 
provoke an immune response, many scientists are working on a solution. 
Several means of transport are being considered, primarily the use of viruses as
vectors or the use of nanotechnology. Adeno associated viruses (AAV) have 
been assembled to target cells in different tissues from the human body. With 
this vector, the CRISPR-Cas9 technology was able to repair muscle cells in 
mice with Duchenne muscular dystrophy (120) and to target the liver and cure 
mice of tyrosinemia (121). There are different AAV vectors that target lung, 
brain, and retinal cells, that could potentially be used in the near future to cure 
diseases such as Huntington, congenital blindness or cystic fibrosis, among 
many others.  
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Pharmaceuticals such as Bayer are trying to develop CRISPR based drugs to 
treat afflictions such as blood disorders, blindness, and heart disease. This 
could conceivably create a new line of treatments, an injection or pill that could 
possibly treat frequent genetic disorders (122).
Fig. 13:  Different approaches for CRISPR-based gene therapies. From (141)
(A) In in vivo editing, CRISPR-Cas9 components are injected directly into the 
patient using vectors for in situ gene editing. 
(B) In ex vivo, genes are edited in patient-derived cells and are transplanted 
back into the same patient after the correction. 
Germline editing is also one of the most promising possibilities of this 
technology. The editing reagents can be introduced into the embryos created 
through in vitro fertilization (IVF). The biggest benefit of this process is it not 
only eliminates the disease from that individual but also from all its 
descendants. The problem with this technology is that, at present, it lacks 
specificity and efficiency to be completely safe. First, the results of genetically 
modified embryos needs a decrease in mutations generated at non-target sites 
before it can be applied to treat embryos, since any changes made with this 
technology will not be reversible (123). Despite this, there is already a case 
reported were two twin girls were born with edited genomes in China. He 
Jiankui was the first to alter the DNA of human embryos during in vitro 
fertilization (133). Since there are hundreds of scientists researching this line of 
work, it is easy to predict its use in the near future.
Once germline editing is a feasible treatment, many hereditary cancers, among 
other diseases, could be prevented. Some would be just as easy as a one letter
change in the embryos genome, like the one shown in the case study analyzed 
in this paper. 
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Case study analysis:
CRISPR- Cas9 is a revolutionary technology thanks to its simplicity and 
specificity.  In this case study, we outline the experimental work prior to the in 
vitro study of CRISPR-Cas9 in the BRCA1 gene. This pertaining SNP, 
rs886040335, is the one responsible for hereditary breast and ovarian cancer. A
single nucleotide change, an A for a G, would repair the genetic alteration, 
resulting in a perfectly healthy patient. 
For the in vitro study to be successful, reliable guide RNAs are essential, so 
they can guide the cas9 protein to the exact location that needs to be cut. In this
case study the “CRISPR design” web page was used to help select both guide 
RNAs. It is a very reliable program which highlights guides with a high target 
specificity and arranges all possible guides by the inverse likelihood of off-target
binding.  Even so, the use of more than one web page to choose the optimal 
guide RNAs, would make the chosen guides more reliable and with fewer off-
targets. Other internet programs to compare possible guide RNAs could be 
CHOP-CHOP or GenScript.    
 There is a significant amount of off-targets warranted by the Cas9 enzyme. 
Many scientists have created variants of the guide RNA or the Cas9 enzyme 
with an increased specificity (124). Church Zhang proved that the combination 
of two mutant Cas9 enzymes, each one cleaving a single strand of DNA, could 
be used to cut opposite strands, leading to a double-stranded cut with a 
reduced off-target activity (125). This modified Cas9 enzymes could be 
considered a viable alternative to improve this case study. 
 An important factor related to off-site targets is the amount of Cas9 enzyme. 
The appropriate amount of cas9 enzyme would have to be taken into 
consideration, before introducing all the reagents into the cell. A high 
concentration of Cas9 increases off-targets, whereas a low concentration 
diminishes the cleavage activity on the target (126). 
Future studies will make progress in the accuracy of the technology by 
designing Cas9 variants, as well as further understanding the conformational 
rearrangements of Cas9 prior to target cleavage. This could all improve the site-
specific insertion of new genetic information, making this case study even more 
reliable in vitro. 
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Ethical implications:
With the emergence of the CRISPR Cas system and all its potential, many 
ethical concerns arose. Some ethical issues to be considered were:
1- The circumstances in which CRISPR technology should be used and its 
safety.
2- The possibility of inheritable changes in the genome of human embryos. 
3- If there should be an international organization or legislation created to 
regulate CRISPR applications.
4- The access to CRISPR technology.
While using this technology it is possible for off targets and mosaicism to occur, 
this makes safety one of the main concerns. Scientists and people who know of 
this technology, such as those present at the International Summit on Human 
Gene Editing in December 2015, concur that until it is a safe procedure it should
not be used for clinical reproductive purposes. With the knowledge we have 
today, the risks of introducing unpredictable mutations in future generations are 
greater than its benefit as a treatment, therefore it would go against the principle
of non- maleficence (127). 
We must also consider that gene-editing also has secondary effects. Editing the
CCR5 gene not only gives the patient a resistance to HIV but a higher 
susceptibility to the West Nile virus and editing the beta-globin gene in a patient 
with sickle cell disease could cure them of its illness but the patient would lose 
its protection against malaria. Editing any gene will always result in a risk of 
unforeseen effects. But just because we do not know its side effects doesn't 
mean we have to renounce germline editing, as George Church said: “The 
notion that we need complete knowledge of the whole human genome to 
conduct clinical trials of heritable gene editing seems at odds with medical 
reality”.  Prior to this treatment, countless others have been used without their 
entire comprehension, so there is no reason for holding CRISPR to a higher 
standard of safety. As long as we edit the gene to its “normal” version the 
benefits will outweigh the risks, without taking into consideration human 
enhancement. 
The biggest ethical concern centers around changing the genome of human 
embryos, due to the fact that any change would be then passed on to 
succeeding generations. Some people have moral and religious beliefs against 
using human embryos for research, they may regard the embryo as a person 
from conception or think of it as something unnatural.  But when considering 
medicine as a whole “the distinction between natural and unnatural is a false 
dichotomy, and if it prevents us from alleviating human suffering, it’s also a 
dangerous one.” (128) Some bioethicists regard germline editing as a way to 
alter humanity itself and its invaluable evolutionary inheritance. While others, 
including bioethical and research groups, find it essential to solving many 
questions about human development. 
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Some bioethicists like Julian Savalescu argue that gene editing “could virtually 
eradicate genetic birth defects” and that “research into gene-editing is not an 
option, it is a moral necessity.” However other bioethicists approve of genome 
editing on embryos for research but are opposed to its clinical application. 
This debate was already present in our society since we developed other 
methods of genetic manipulation, such as TALENs, and we started using 
preimplantation genetic diagnosis (PGD) and in-vitro fertilization (IVF). This 
ongoing debate regained attention after the discovery of CRISPR because it 
makes genetic manipulation an easier and more accurate process. Some 
scientists claim that genome editing may never have a greater benefit than 
methods such as PGD and IVF. However, in some cases in which PGD is 
ineffective genome editing may prove useful. For example, when both parents 
are homozygous for a disease, so if they were to have children they would all 
have the disease or cases of polygenic diseases where there is more than one 
gene causing the disease. On one hand, some ethicists argue that using this 
technology will start a slippery slope that will have humans using it to upgrade 
the human genome in a quest for perfection. On the other hand, some believe 
once it is studied and safe it could potentially eradicate disease and avoid 
serious genetic defects, while concerns about the technology being abused 
should be considered through laws and policies (129).
Furthermore, there are concerns about the use of genome editing for 
reproductive purposes being regulated differently throughout the world, just like 
PGD and IVF have differences in their policies worldwide. In M. Araki and T. 
Ishii’s study published in 2014, 39 countries policies regarding the editing of the 
human genome were studied. 
Fig. 14: International regulation of human genome editing. From (130).
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Out of these 39 countries, 29 had a ban on this kind of research, shown in dark 
and light pink on the map. But while the 25 countries in dark pink have laws 
banning this practice the remaining 4 in light pink only have guidelines that ban 
this kind of studies, there are not enforceable laws. The remaining countries 
(grey on the map) had ambiguous guidelines pertaining to this studies, although
USA (light grey) does have a restrictive set of rules. 
This study shows that while there are countries such as Austria where “any 
intervention involving the human germline is prohibited” there are others such 
as China, Japan or USA that only have certain guidelines and might use these 
techniques once they become safer (130). This disparities between countries 
could encourage CRISPR tourism, patients with means could travel to countries
where regulations are more lax or absent altogether.
Due to this disparity in regulations, there are some international organizations, 
which include the USA, UK, and China, trying to unify the regulation for the 
application of the CRISPR technologies. This endeavor started in the 
“International Summit on Human Gene Editing” in December 2015 (127). 
According to Doudna: “Nations need to maintain regulatory environments that 
are hospitable enough to permit research and clinical applications but strict 
enough to prevent the worst excesses.” It is unrealistic to think we will come to 
an agreement worldwide on how to use this technology but it would certainly be 
beneficial for everyone if governments tried to unify their policies on germline 
editing.    
Once this technology is safe enough for clinical applications to prevent genetic 
diseases there should be further discussions and ethical considerations to avoid
its abuse. The Hinxton Group, an international consortium on stem cells ethics 
and law, acknowledge that “when all safety, efficacy and governance needs are 
met, there may be morally acceptable uses of this technology in human 
reproduction, though further substantial discussion and debate will be required.”
Some uses of this technology in embryos may be accepted, when it prevents a 
child from inheriting a disease, while other uses might be forbidden, such as 
genetic enhancement. 
Once this technology is fully developed and functional we have to acknowledge 
it might be used for genetic enhancements. There is not a clear line between 
what is classified as a medical treatment and a genetic enhancement. If the 
gene PCSK9 is edited the patient will reduce their risk of heart disease due to 
low cholesterol, editing the APOE gene will diminish the patients’ risk of 
Alzheimer’s disease, etc. There are numerous examples were editing a gene 
reduces the persons’ risk of developing a disease but it also provides those 
individuals with an above average genome. This is without taking into 
consideration non-medical enhancements were some scary possibilities will be 
viable and at everyone’s disposal, like creating super soldiers or the perfect 
race.
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Just like its hard to know where the line between medical treatment and 
enhancement is, its hard to see how this could be done equitably. There are 
concerns about this technology only being accessible to the wealthy which 
would generate even bigger discrepancies in health care between the rich and 
the poor. Taken to the extreme, editing genomes could create different classes 
of humans depending on the quality of their engineered genome. The wealthy 
would live healthier and longer lives. 
Moreover, who decides which therapies should we develop? There are obvious 
candidates like cancer, Huntington or cystic fibrosis but what about familial short
stature or hereditary deafness? Many people with this conditions think there is 
nothing to “correct” about them (128). Should we consider cosmetic changes? 
Humans tend to try to get physical perfection, assuming this could be obtained 
with CRISPR-Cas9, should this be pursued? 
This technology raises many ethical issues that are non-human related too, like 
the risks taken by generating enhanced animals or plants or the risk of 
generating a worldwide ecological impact. Given the great opposition against 
GMOs in agriculture, this technique could face the same opposition if the 
general public were misinformed. 
Since it is society as a whole who should decide how to use this technology it is 
up to scientists to educate the people so they can make an informed decision. 
(128)
 
37
CONCLUSION
 
The CRISPR-Cas arose from studying the archaea and bacteria immune 
systems and has become the most precise genome editing technology. Studies 
using CRISPR-Cas technology have increased in recent years, revealing its 
potential in modern medicine. Many clinical trials are in progress to use ex-vivo 
and in-vivo somatic cell editing in patients, since this technology has enabled in-
depth studies of our genome and the means to edit any specific gene. 
In the near future, editing the human genome with CRISPR-Cas9 will aid in the 
treatment of genetic and infectious diseases, as well as cancer.  Although some
challenges remain, CRISPR-Cas technology will become a safe and applicable 
method used in a variety of therapeutic approaches. 
The BRCA1 study shown in this report demonstrates the simplicity and potential
of this technology, it enables a fast and cheap procedure, were a single 
nucleotide can be modified, eliminating hereditary breast and ovarian cancer 
from the patients cells. 
The uses of CRISPR-Cas system goes beyond medical applications, 
contributing in advancing modern agriculture and biotechnology. Some of the 
numerous applications in this field are crop editing, gene drives or synthetic 
biology. 
CRISPR-Cas9 provides endless possibilities to improve the world. This 
technology could be used to eradicate genetic diseases, to cure cancer or even 
solve the worlds hunger crisis. The possibilities are countless. However, genetic
engineering is a highly controversial societal issue. Unifying governmental 
policies around the world on how to use this technology safely should be 
addressed in the near future, focusing on policies concerning germline editing.
Once used to change the human germline, it will alter the human genome in a 
heritable way. While some scientists find the use of this technology immoral, 
others like Doudna, believe it is “unethical to not ease human suffering when it 
is in our hands.” This poses new questions: how can society choose which 
ways to use this technology and when to restrict or ban its use?
It is impossible to unlearn this knowledge or pretend like it is not here to stay. 
The important question now is: are humans ready to have the power to control 
every species’, including our own genetic future? 
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